tbuckley/cabot-search huggingface dataset:
Lentivirus in the Clinic: In Reply
Authors: Greg M. Podsakoff
Journal: Molecular Therapy (2001)

The key issue for the proposed first lentiviral vector clinical study is whether this construct is a safe vector to be applied in the clinic at this time, or whether more thorough characterization of potential outcomes is necessary. The study involves treatment of a lethal disease with a novel vector, which, as Boro Dropulic points out, is “second generation” due to the deletion of the accessory proteins. For this study using the proposed vector, the safety issues are difficult to test, as the in vitro results in cells and mice are limited in their translation to the actual in vivo milieu in human subjects. It is hoped that the inhibitory effects of this vector in vivo are the same as those seen in vitro, and that will ultimately be determined by clinical studies such as this. Vector mobilization at any level is problematic because it may indicate failure of the anti-HIV-1 strategy and lead to unwanted recombination events, which could adversely affect a trial subject. The complete characterization of post-transduction recombinants is important, as a recombinant with altered tropism has serious implications for a patient who is failing HAART. Although the occurrence of a recombinant is more likely to develop during the ex vivo manipulation of cells, the appropriate time frame for subject follow-up before dose escalation is not clear, especially because low-level mobilization may occur. As safety testing is being analyzed without an adequate animal model, it is difficult to separate those issues that are real from those that are theoretical. A critical and challenging issue remains in the development of a sensitive, validated method for the exclusion of RCL and the VSV-G gene in the setting of large numbers (> 1010) of lentivector-transduced, HIV-1-infected lymphocytes. The outcome of the interaction between VIRxSYS and the Food and Drug Administration is important for all of those who look for guidance to pursue this promising new vector system in the clinic. Lentivirus in the ClinicBORO DROPULICMolecular TherapyDecember, 2001In BriefTo the Editor Full-Text PDF Open Archive
Diet and Health with Key to the Calories.
Authors: Lulu Hunt Peters
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Caring for the Fourth Age: A Practical Guide to Medical Problems in Old Age, by J J Oram
Authors: W J MacLennan
Journal: BMJ (1997)

J J Oram Armelle Press, £16, pp 223 ISBN 0 953 10700 0

The increasing number of very old people with physical and mental incapacity has necessitated a continuing supply of simple, succinct, and practical books for lay carers and professionals. Dr Oram's response is a book that deals with the “giants of geriatrics” (mental impairment, falls, immobility, and incontinence), other common diseases of old age, and miscellaneous topics such as ethics, rehabilitation, and the demography …
James Alexander ("Hamish") Chalmers Norman Creighton Thomas Hugh English Roger Philip Golding John Richard Hewett Arthur Richard ("Dick") Kittermaster Anthony Robert Lyons Dominic William Andrew McCreadie Rosalie Ada Helen Paul Anthony Ferrier Stallard
Authors: R. Johanson, M. Hall, J. Harris, R. Brown, G. Morgan, D. Bradford, P M O Massey, W A. Wallace, D. McCreadie, H. H Gebbie, S. Stallard
Journal: BMJ (1998)
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation
Authors: Edgar Turner Overton, Ellen S. Chan, Todd T. Brown, Pablo Tebas, Grace A. McComsey, Kathleen M. Melbourne, Andrew Napoli, William Royce Hardin, Heather J. Ribaudo, Michael T. Yin
Journal: Annals of Internal Medicine (2015)

Background: Antiretroviral therapy initiation for HIV-1 infection is associated with 2% to 6% loss of bone mineral density (BMD). Objective: To evaluate the effect of vitamin D3 plus calcium supplementation on bone loss associated with antiretroviral therapy initiation. Design: 48-week prospective, randomized, double-blind, placebo-controlled study. (ClinicalTrials.gov: NCT01403051) Setting: 39 AIDS Clinical Trials Group units. Patients: Adults with antiretroviral therapy–naive HIV. Measurements: BMD by dual-energy x-ray absorptiometry, 25-hydroxyvitamin D levels, and other laboratory assessments. Results: 165 eligible patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo). The study groups were well-balanced at baseline: 90% were men, 33% were non-Hispanic black, and the median CD4 count was 0.341 × 109 cells/L. At 48 weeks, the percentage of decline in total hip BMD was smaller in the vitamin D3 plus calcium group than in the placebo group: Medians were −1.36% (interquartile range [IQR], −3.43% to 0.50%) and −3.22% (IQR, −5.56% to −0.88%), respectively ( P = 0.004). Similar results were seen at the lumbar spine. At 48 weeks, 90% of patients achieved HIV-1 RNA levels less than 50 copies/mL. Levels of 25-hydroxyvitamin D3 increased with vitamin D3 plus calcium but not with placebo: Median change was 61.2 nmol/L (IQR, 36.4 to 94.3) versus 1.7 nmol/L (IQR, −13.2 to 10.7) (P < 0.001). Overall, 103 patients (62%) reported 1 or more adverse event, with similar distribution between groups; no cases of hypercalcemia and 1 case of nephrolithiasis were reported in the placebo group. Limitation: No international sites were included, and follow-up was only 48 weeks. Conclusion: Vitamin D3 plus calcium supplementation mitigates the BMD loss seen with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate. Primary Funding Source: National Institute of Allergy and Infectious Diseases, Bristol-Myers Squibb, and Gilead Sciences.
Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses
Authors: Martin Kolev, Sarah Dimeloe, Gaelle Le Friec, Alexander Navarini, Giuseppina Arbore, Giovanni A. Povoleri, Marco Fischer, Réka Belle, Jordan Loeliger, Leyla Develioglu, Glenn R. Bantug, Julie Watson, Lionel Couzi, Behdad Afzali, Paul Lavender, Christoph Hess, Claudia Kemper
Journal: Immunity (2015)

Expansion and acquisition of Th1 cell effector function requires metabolic reprogramming; however, the signals instructing these adaptations remain poorly defined. Here we found that in activated human T cells, autocrine stimulation of the complement receptor CD46, and specifically its intracellular domain CYT-1, was required for induction of the amino acid (AA) transporter LAT1 and enhanced expression of the glucose transporter GLUT1. Furthermore, CD46 activation simultaneously drove expression of LAMTOR5, which mediated assembly of the AA-sensing Ragulator-Rag-mTORC1 complex and increased glycolysis and oxidative phosphorylation (OXPHOS), required for cytokine production. T cells from CD46-deficient patients, characterized by defective Th1 cell induction, failed to upregulate the molecular components of this metabolic program as well as glycolysis and OXPHOS, but IFN-γ production could be reinstated by retrovirus-mediated CD46-CYT-1 expression. These data establish a critical link between the complement system and immunometabolic adaptations driving human CD4+ T cell effector function.
Relation Between Contractile Reserve and Positron Emission Tomographic Patterns of Perfusion and Glucose Utilization in Chronic Ischemic Left Ventricular Dysfunction
Authors: Pierre G Mélon, Christian M de Landsheere, Christian Degueldre, Jean-Luc Peters, Henri E Kulbertus, Luc A Piérard
Journal: Journal of the American College of Cardiology (1997)
Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship
Authors: Tommaso Cai, Paolo Verze, Anna Brugnolli, Daniele Tiscione, Lorenzo Giuseppe Luciani, Cristina Eccher, Paolo Lanzafame, Gianni Malossini, Florian M E Wagenlehner, Vincenzo Mirone, Truls E Bjerklund Johansen, Robert Pickard, Riccardo Bartoletti
Journal: European Urology (2015)
Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes
Authors: V. Von Felbert, G. Hoffmann, S. Hoff-Lesch, F. Abuzahra, C.N. Renn, L.R. Braathen, H.F. Merk
Journal: British Journal of Dermatology (2010)

Journal Article Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water‐filtered infrared A compared with light from light‐emitting diodes Get access V. Von Felbert, V. Von Felbert Department of Dermatology, RWTH Aachen University, 52074 Aachen, Germany Verena von Felbert. E‐mail: vvonfelbert@ukaachen.de Search for other works by this author on: Oxford Academic Google Scholar G. Hoffmann, G. Hoffmann Institute of Sports Sciences, Johann Wolfgang Goethe University, Frankfurt/Main, Germany Search for other works by this author on: Oxford Academic Google Scholar S. Hoff‐Lesch, S. Hoff‐Lesch Department of Dermatology, RWTH Aachen University, 52074 Aachen, Germany Search for other works by this author on: Oxford Academic Google Scholar F. Abuzahra, F. Abuzahra Department of Dermatology, RWTH Aachen University, 52074 Aachen, GermanyDepartment of Dermatology, Zaans Medisch Centrum, Zaandam, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar C.N. Renn, C.N. Renn Department of Dermatology, RWTH Aachen University, 52074 Aachen, Germany Search for other works by this author on: Oxford Academic Google Scholar L.R. Braathen, L.R. Braathen Department of Dermatology, Inselspital, University of Bern, Bern, Switzerland Search for other works by this author on: Oxford Academic Google Scholar H.F. Merk H.F. Merk Department of Dermatology, RWTH Aachen University, 52074 Aachen, Germany Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 3, 1 September 2010, Pages 607–615, https://doi.org/10.1111/j.1365-2133.2010.09817.x Published: 01 September 2010
CPAP, Surfactant, or Both for the Preterm Infant
Authors: Peter A. Dargaville
Journal: JAMA Pediatrics (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy
Authors: Charles D. Kassardjian, Vanda A. Lennon, Nora B. Alfugham, Michael Mahler, Margherita Milone
Journal: JAMA Neurology (2015)

IMPORTANCENecrotizing autoimmune myopathy (NAM) is characterized pathologically by necrotic muscle fibers with absent or minimal inflammation.It is often accompanied by statin therapy, connective tissue diseases, cancer, and autoantibodies specific for signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR).Data are limited concerning differences among etiologic subgroups and treatment outcomes in NAM.OBJECTIVES To describe the clinical, serologic, and electrophysiologic characteristics of NAM, compare patient subgroups, and determine clinical outcome predictors. DESIGN, SETTING, AND PARTICIPANTSWe conducted a retrospective review of medical records for 63 adult Mayo Clinic patients assigned the clinical and histopathologic diagnosis of NAM from January 1, 2004, through December 31, 2013.Patients were stratified by presumed cause and autoantibody status.MAIN OUTCOMES AND MEASURES Clinical, electrophysiologic, and pathologic characteristics were collected and compared among patient subgroups.Predictors of response to treatment were identified by univariate logistic regression. RESULTS Lower extremity weakness predominated (46 [73%]). Distal weakness (26 [41%]), dysphagia (22 [35%]), and dyspnea (23 [37%]) were common.Twenty-two patients (35%) were receiving a statin medication at onset, 6 had cancer, and 3 had a connective tissue disease.The median creatine kinase level was 5326 U/L.In 13 patients (24%), SRP-IgG was detected, and in 17 patients (34%), HMGCR-IgG was detected (one-third of whom had not received statin medication).One patient was dual seropositive.Facial weakness was more common in SRP-IgG-positive patients.Myotonic discharges were more common in statin-associated NAM.Prednisone monotherapy was insufficient to control disease in most patients; 30 (90%) of 32 patients required 2 or more immunotherapeutic agents.Relapse occurred in 16 (55%) of 29 patients during immunosuppressant taper or discontinuation.Predictors of favorable outcome were male sex and use of 2 or more immunotherapeutic agents within 3 months of onset.CONCLUSIONS AND RELEVANCE Necrotizing autoimmune myopathy was idiopathic in half of this cohort with clinical and histopathologically defined disease.In the remainder, NAM was associated with statin medication, cancer, or connective tissue disease.One in 4 patients was SRP-IgG positive, and 1 in 3 was HMGCR-IgG positive.The disease was usually not controlled by corticosteroid monotherapy.Presentation, course, and outcomes did not differ significantly in seropositive, seronegative, and statin-associated cases.Early aggressive immunosuppressant therapy improved outcomes, and risk of relapse was high during medication dose reduction or withdrawal.
Abstract 28: Deregulation of NAC complex inhibits muscle differentiation and blocks apoptosis in rhabdomyosarcoma cells
Authors: Meiling Zhang, Judith Davie
Journal: Cancer Research (2015)

Abstract Rhabdomyosarcoma (RMS) is a common malignant soft tissue sarcoma in children with limited treatment options and high failure rate during standard therapy. New therapeutic targets or strategies are therefore in high demand. The NAC complex performs many diverse biological functions, and the deregulation of its subunits has been correlated with many cancers. We sought to understand the function of NAC complex in normal muscle cells and rhabdomyosarcoma cells. With western blot, quantitative real time PCR (qRT-PCR), chromatin immunoprecipitation and immunostaining analysis, we found that the muscle specific subunit of NAC complex, skNAC, which is the alternatively spliced isoform of NACα, was downregulated in RMS cells. In normal cells, skNAC shuttled from the cytoplasm to the nucleus upon differentiation. We also showed that skNAC associated with muscle specific promoters together with BTF3 in differentiated cells, and this association is dependent on the expression of BTF3. The expression of skNAC was regulated by the splicing factor SRPK3, a serine arginine protein kinase. Overexpression of SPRK3 induced skNAC expression and muscle differentiation. We also detected the deregulation of another NAC complex subunit, NACβ (also known as BTF3). We found that BTF3 is highly overexpressed and localized in the nucleus in both RMS cell lines and human RMS tumor samples compared with normal samples. Depletion of BTF3 induced apoptosis as detected by the strong cleavage of PARP and caspase 3. BTF3 depletion also decreased the cell viability in RMS by a cologenic assay. We also confirmed that BTF3 downregulation promoted muscle gene expression and induced muscle differentiation in RMS cells. However, BTF3 played a different role in normal cells. With the deletion of BTF3 in C2C12 cells, no apoptosis signal was detected and cell differentiation was inhibited, which suggested that a precise level of BTF3 is important for normal cell function. In conclusion, we found that the NAC complex subunits, skNAC and BTF3, were deregulated in RMS cells. The restoration of skNAC by SRPK3 overexpression rescued muscle differentiation. BTF3 functioned as an anti-apoptosis factor in RMS cells and depletion of BTF3 induced apoptosis and promoted differentiation. With no apoptosis effect in normal cells, BTF3 could serve as a cancer specific therapeutic target in RMS cells. Citation Format: Meiling Zhang, Judith Davie. Deregulation of NAC complex inhibits muscle differentiation and blocks apoptosis in rhabdomyosarcoma cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 28. doi:10.1158/1538-7445.AM2015-28
679. Systemic Delivery and Tumor Gene Expression Using Polycation-Precondensed DNA Prepared as Stable Plasmid Lipid Particles
Authors: Lorne Palmer, Lloyd B. Jeffs, Kitty P. Y. Chan, Kevin McClintock, Cory Giesbrecht, James Heyes, Amy C. H. Lee, Ian MacLachlan
Journal: Molecular Therapy (2004)
Effectiveness of Influenza Vaccine to Prevent Acute Otitis Media—Reply
Authors: Alejandro Hoberman, David P. Greenberg, Jack L. Paradise
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17425: Curcumin Ameliorates Experimental Autoimmune Myocarditis by Inducing M2 Macrophage Polarization
Authors: Shanshan Gao, Na Liu, Lijun Wang, Fangyuan Chen, Hongjun You, Yang Liu, Juan Zhou, Zuyi Yuan
Journal: Circulation (2014)

AIMS: Our previous study showed that curcumin, the main active ingredient in turmeric, induces the polarization of macrophages to anti-inflammatory M2 phenotype. In this study, we addressed the underlying mechanisms and observed whether curcumin exerts its protective effects on experimental autoimmune myocarditis (EAM) by facilitating the M2 phenotype polarization of macrophages. METHODS AND RESULTS: The mRNA and protein expression of M2 markers, including MMR, Arg-1, KLF-4 and PPAR-γ, were obviously up-regulated in curcumin-treated RAW264.7 macrophages. Curcumin increased not only IL-4 and IL-13 mRNA expression, but also protein content of these two cytokines in supernatant. The STAT6 inhibitor leflunomide antagonized the induction of MMR, Arg-1, KLF-4 and PPAR-γ by curcumin in RAW264.7 cells, which is suggested that curcumin induces macrophages M2 polarization through secretion of IL-4 and IL-13 in an autocrine manner. In vivo, 6-week-old male Lewis rats were immunized with myosin to induce EAM and orally administrated with curcumin (50mg/kg/day) or corn oil for 3 weeks after myosin injection. Cardiac functional parameters, including LVFS, EF, LVESD and HR, were significantly improved by curcumin treatment. Curcumin also reduced the heart weight-to-body weight ratio, inflammatory cell infiltration and the myocardial mRNA level of IL-1β and iNOS. Meanwhile, the myocardial mRNA level of KLF4, MMR and Arg-1 were markedly up-regulated by curcumin. Immunofluorescence assay showed that the number of CD68+MMR+ and CD68+Arg-1+ double positive macrophages in curcumin-treated myocardial tissue was obviously more than vehicle-treated ones. CONCLUSIONS: Taken together, these results show that curcumin ameliorates EAM by attenuating inflammation and by inducing macrophage M2 polarization.
A G-to-A mutation in IVS-3 of the human gamma fibrinogen gene causing afibrinogenemia due to abnormal RNA splicing
Authors: Maurizio Margaglione, Rosa Santacroce, Donatella Colaizzo, Davide Seripa, Gennaro Vecchione, Maria Rosaria Lupone, Domenico De Lucia, Paolo Fortina, Elvira Grandone, Corrado Perricone, Giovanni Di Minno
Journal: Blood (2000)
Risk-Treatment Mismatch for Heart Failure
Authors: Samy Suissa
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal